Tegra Medical Achieves ISO 14001 Environmental Management Certification

Tegra Medical, a leading contract manufacturer of medical devices and a member of SFS, which is headquartered in Heerbrugg Switzerland, today announced it has achieved ISO 14001 certification in all four of its locations in the Americas.

ISO 14001 certification, the world’s most widely recognized standard for Environmental Management Systems, is granted to companies that identify and manage aspects of their business to reduce their environmental impact. Certification is established with a baseline, which is determined after an extensive audit of a company’s procedures.

The audit is followed by a plan for improvement in selected areas. Some of Tegra Medicals areas upon which to focus improvement include material reuse, waste reduction, composting, and evaluating equipment for age and power efficiency. The Costa Rica location already gets nearly all its energy from renewable sources.
“Tegra Medical is emphatically committed to contributing to a greener world for future generations,” said Walter Kobler, Tegra Medical CEO. “As the medical division of SFS, Tegra Medical has made sustainability part of its DNA. It’s a mindset that will deliver value to our stakeholders as we infuse the holistic ESG criteria (environmental, social, governance) into all the work we do.”

Eduardo Mena leads the quality, environmental, health, and safety activities for Tegra Medical from the company’s location in Costa Rica. “The hard work of obtaining ISO 14001 certification will not only benefit our planet but will bring efficiencies in many of our manufacturing processes,” Mena noted. “With certification we will have processes in place to gauge improvements such as waste reduction, as well as our continuing efforts in becoming a greener company.”

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.